María Sierra Girón-Prieto1, Salvador Arias-Santiago2, María Del Carmen Cano-García3,4, Antonio Poyatos-Andújar5, Tomás de Haro-Muñoz6, Felix Abad-Menor3,4, Miguel Quesada-Charneco7, Miguel Ángel Arrabal-Polo8,9, Miguel Arrabal-Martín3,4. 1. Centro de Salud de Pinos Puente, Programa de Doctorado de Medicina Clínica y Salud Pública, Universidad de Granada, Granada, Spain. 2. Facultad de Medicina, Universidad de Granada, Granada, Spain. 3. UGC Urologia, Complejo Hospitalario Universitario Granada, Dr Virgili street, 9, bajo C. Huercal Overa, 04600, Granada, Spain. 4. Instituto IBS Granada, Granada, Spain. 5. UGC Analisis Clinicos, Hospital Santa Ana, Motril, Granada, Spain. 6. UGC Analisis Clinicos, Hospital Universitario Granada, Granada, Spain. 7. UGC Endocrinología, Complejo Hospitalario Universitario Granada, Granada, Spain. 8. UGC Urologia, Complejo Hospitalario Universitario Granada, Dr Virgili street, 9, bajo C. Huercal Overa, 04600, Granada, Spain. arrabalp@ono.com. 9. Instituto IBS Granada, Granada, Spain. arrabalp@ono.com.
Abstract
PURPOSE: To analyze the presence of phosphocalcic metabolism disorders in patients with osteopenia-osteoporosis without nephrolithiasis with respect to a control group. METHODS: A cross-sectional study was conducted in patients with osteopenia-osteoporosis without nephrolithiasis (n = 67) in lumbar spine or femur and in a control group (n = 61) with no lithiasis or bone disorders. Blood bone markers, phosphocalcic metabolism, fasting urine, 24-h urine lithogenic risk factors, and densitometry were recorded in both groups. SPSS 20.0 was used for statistical analysis. RESULTS: In comparison with the controls, significantly higher blood calcium (9.27 ± 0.36 vs. 9.57 ± 0.38, p = 0.0001), intact parathormone (45.6 ± 14.9 vs. 53.8 ± 18.9, p = 0.008), and alkaline phosphatase (61.9 ± 20.9 vs. 70.74 ± 18.9, p = 0.014) levels were found in patients with osteopenia-osteoporosis. In the 24-h urine test, citrate (1010.7 ± 647.8 vs. 617.6 ± 315.8, p = 0.0001) and oxalate (28.21 ± 17.65 vs. 22.11 ± 16.49, p = 0.045) levels were significantly lower in osteopenia-osteoporosis patients than in controls, with no significant difference in calcium (187.3 ± 106.9 vs. 207.06 ± 98.12, p = 0.27) or uric acid (540.7 ± 186.2 vs. 511.9 ± 167.06, p = 0.35) levels. Patients with osteopenia-osteoporosis had significantly higher levels of lithogenic risk factors associated with bone remodeling, including significantly increased β-crosslaps and osteocalcin values and higher β-crosslaps/osteocalcin ratios. CONCLUSION: Patients with osteopenia-osteoporosis without nephrolithiasis showed phosphocalcic metabolism disorders as well as lower urinary citrate and higher β-crosslaps/osteocalcin and fasting calcium/creatinine ratios, which would increase the risk of nephrolithiasis. Hence, prospective studies are warranted to evaluate the long-term risks.
PURPOSE: To analyze the presence of phosphocalcic metabolism disorders in patients with osteopenia-osteoporosis without nephrolithiasis with respect to a control group. METHODS: A cross-sectional study was conducted in patients with osteopenia-osteoporosis without nephrolithiasis (n = 67) in lumbar spine or femur and in a control group (n = 61) with no lithiasis or bone disorders. Blood bone markers, phosphocalcic metabolism, fasting urine, 24-h urine lithogenic risk factors, and densitometry were recorded in both groups. SPSS 20.0 was used for statistical analysis. RESULTS: In comparison with the controls, significantly higher blood calcium (9.27 ± 0.36 vs. 9.57 ± 0.38, p = 0.0001), intact parathormone (45.6 ± 14.9 vs. 53.8 ± 18.9, p = 0.008), and alkaline phosphatase (61.9 ± 20.9 vs. 70.74 ± 18.9, p = 0.014) levels were found in patients with osteopenia-osteoporosis. In the 24-h urine test, citrate (1010.7 ± 647.8 vs. 617.6 ± 315.8, p = 0.0001) and oxalate (28.21 ± 17.65 vs. 22.11 ± 16.49, p = 0.045) levels were significantly lower in osteopenia-osteoporosispatients than in controls, with no significant difference in calcium (187.3 ± 106.9 vs. 207.06 ± 98.12, p = 0.27) or uric acid (540.7 ± 186.2 vs. 511.9 ± 167.06, p = 0.35) levels. Patients with osteopenia-osteoporosis had significantly higher levels of lithogenic risk factors associated with bone remodeling, including significantly increased β-crosslaps and osteocalcin values and higher β-crosslaps/osteocalcin ratios. CONCLUSION:Patients with osteopenia-osteoporosis without nephrolithiasis showed phosphocalcic metabolism disorders as well as lower urinary citrate and higher β-crosslaps/osteocalcin and fasting calcium/creatinine ratios, which would increase the risk of nephrolithiasis. Hence, prospective studies are warranted to evaluate the long-term risks.
Entities:
Keywords:
Bone markers; Lithogenic factors; Osteopenia; Osteoporosis
Authors: John R Asplin; Kimberly A Bauer; Jennifer Kinder; Georg Müller; Brian J Coe; Joan H Parks; Fredric L Coe Journal: Kidney Int Date: 2003-02 Impact factor: 10.612
Authors: Miguel Angel Arrabal-Polo; Miguel Arrabal-Martin; Antonio Poyatos-Andujar; Encarnacion Cardenas-Grande; Sergio Merino-Salas; Armando Zuluaga-Gomez Journal: Urol Res Date: 2011-12-04
Authors: Sheila O'Neill; Alastair MacLennan; Shona Bass; Terry Diamond; Peter Ebeling; David Findlay; Leon Flicker; Alex Markwell; Caryl Nowson; Nick Pocock; Philip Sambrook; Maria Fiatarone Singh Journal: Aust Fam Physician Date: 2004-11
Authors: Miguel Angel Ochoa-Hortal Rull; María Del Carmen Cano-García; Miguel Arrabal-Martín; Miguel Angel Arrabal-Polo Journal: Can Urol Assoc J Date: 2015 Mar-Apr Impact factor: 1.862